Phoenix Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

Phoenix Financial’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,237	Closed	-$389K	–	398
2024 Q1	$389K	Buy	+3,237	New	+$397K	0.01%	292
2023 Q4	–	Sell	-4,514	Closed	-$593K	–	363
2023 Q3	$593K	Sell	4,514 -3,361	-43%	-$448K	0.01%	252
2023 Q2	$974K	Buy	+7,875	New	+$1.06M	0.02%	216

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Phoenix Financial's JAZZ Position: Q2 2024 in Review

Phoenix Financial sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 3,237 shares — an estimated $389K sold.

Phoenix Financial first reported a position in JAZZ in Q2 2023 and held it in 3 quarters. The position peaked at $974K in Q2 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Phoenix Financial reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Phoenix Financial sold 3,237 Jazz Pharmaceuticals shares in Q2 2024, an estimated $389K.
Phoenix Financial first reported a position in Jazz Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Phoenix Financial's Jazz Pharmaceuticals position peaked at $974K in Q2 2023.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Phoenix Financial's 13F filing for Q2 2024, filed 12 Aug 2024.